Factor V Leiden Clinical Manifestations
Factor V Leiden primarily manifests as venous thromboembolism (VTE), with deep venous thrombosis (DVT) and pulmonary embolism (PE) being the most common presentations, though thrombosis in unusual venous sites and pregnancy-related complications also occur. 1
Primary Venous Manifestations
Standard VTE Presentations
- Deep venous thrombosis (DVT): Most common manifestation, occurring in approximately 19% of heterozygotes and 1% of homozygotes among all VTE patients 2
- Pulmonary embolism (PE): Present in 8% of heterozygotes and 0.3% of homozygotes among isolated PE cases 2
- Combined DVT and PE: Occurs in 15% of heterozygotes and 1% of homozygotes 2
The risk is substantially higher in men, with Factor V Leiden being 2.3 times more likely to manifest clinically in males than females 3. The first lifetime episode typically occurs after age 50 years, contrary to common assumptions about early presentation 1.
Unusual Site Thromboses
Factor V Leiden causes thrombosis in atypical venous locations 1:
- Hepatic veins
- Mesenteric veins
- Cerebral veins
- Inferior vena cava (can present as IVC syndrome with massive occlusive thrombus) 4
Pregnancy-Related Manifestations
Factor V Leiden significantly increases obstetric complications through placental thrombosis 1:
- Recurrent fetal loss: Increased risk, potentially treatable with antithrombotic therapy 1
- Severe preeclampsia: 2- to 3-fold increased relative risk 5
- Placental abruption: Associated with the mutation 1
- Intrauterine fetal growth retardation: Unexplained cases linked to Factor V Leiden 1
- Stillbirth: Increased occurrence 1
- Postpartum VTE: Particularly high-risk period requiring heightened vigilance 1
Despite these risks, the probability of successful pregnancy outcome remains high 5.
Arterial Manifestations (Limited)
Arterial thrombosis is generally NOT associated with Factor V Leiden, with one critical exception 1:
- Myocardial infarction in young female smokers (<45 years): The combination increases relative risk 32-fold 1
- Young adults (<50 years) with arterial thrombosis: May be implicated when other atherosclerotic risk factors are absent 1
- General arterial events: Stroke and myocardial infarction show no association in most populations 1
Some older studies suggested arterial events in younger patients (mean age 45.4 years for arterial thromboses), but this remains controversial 6.
Risk Stratification by Genotype
Heterozygotes (Single Mutation)
- Lifetime VTE risk: ~10% 1
- Relative risk for VTE: 6- to 8-fold increase 2
- Annual VTE incidence: 2.9 events per 1,000 persons 2
- Recurrence risk after first VTE: Modest at best, with conflicting evidence 1, 2
Homozygotes (Double Mutation)
- Lifetime VTE risk: >80% 1
- Relative risk for VTE: 80-fold increase 2
- Annual VTE incidence: 15 events per 1,000 persons 2
- Recurrence risk: Significantly elevated (odds ratio 2.65) 2
- Present in only 1.5% of VTE patients under age 70 1
Compound Heterozygotes
Patients heterozygous for both Factor V Leiden and prothrombin 20210A mutation show high recurrence risk and warrant consideration for lifetime anticoagulation 1.
Clinical Modifiers
The clinical expression is heavily influenced by additional factors 5:
- Family history: Positive family history increases VTE risk 2.9-fold; if relative had VTE before age 50, risk increases 5-fold; multiple affected relatives increase risk 17-fold 2
- Oral contraceptives: Substantially amplifies risk in female carriers 1
- Obesity: Increases lifetime VTE risk 1
- Advanced age: Independent risk factor that compounds genetic risk 1
- Surgery/trauma: High-risk periods requiring prophylaxis 1
- Immobility: Circumstantial risk factor 1
- Pregnancy/postpartum: Particularly high-risk period 1
Laboratory Findings
Patients with Factor V Leiden and VTE manifestations often demonstrate:
- Lower protein C levels compared to controls and patients without DVT 3
- Lower protein S levels compared to controls 3
- Activated protein C resistance on functional testing 3
Key Clinical Pitfalls
Age bias: Do not exclude testing in elderly patients—26% of men over age 60 with first idiopathic VTE have Factor V Leiden 1
Asymptomatic carriers: Most heterozygotes (90%) never develop thrombosis despite carrying the mutation 1
Recurrence assessment: Heterozygosity has uncertain impact on recurrence risk, with studies showing conflicting results 1
Arterial disease: Do not routinely test for Factor V Leiden in arterial thrombosis except in young female smokers with MI 1